Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke

NCT00604630 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

522

Enrollment

OTHER

Sponsor class

Conditions

Infarction, Middle Cerebral Artery
Middle Cerebral Artery Stroke
Stroke, Acute

Interventions

DRUG: recombinant human erythropoietin alfa
DRUG: 0.9% NaCl

Sponsor

Max-Planck-Institute of Experimental Medicine

Collaborators

[object Object]
[object Object]